EIKON THERAPEUTICS, INC. Temporary Equity, Liquidation Preference
EIKON THERAPEUTICS, INC. (EIKN) had Temporary Equity, Liquidation Preference of $1.16 billion as of 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2026-08-13
- 2025-12-31: Temporary Equity, Liquidation Preference $1.16B.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2025-12-31 | $1.16B 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |